Alan Bryce, MD
Hematology & Oncology · Scottsdale, AZNPI 1548246655
Payments from drug & device makers
Across 338 payments — averaging $5137.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$973K
- Janssen Research & Development, LLC$261K
- Eli Lilly$128K
- Pharmaand GmbH$81K
- Genentech, Inc.$61K
- Amgen$45K
- plus $188K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 148 | $972,812 |
| Janssen Research & Development, LLC | 29 | $260,759 |
| Eli Lilly | 12 | $127,736 |
| Pharmaand GmbH | 9 | $81,167 |
| Genentech, Inc. | 11 | $61,285 |
| Amgen | 2 | $45,093 |
| Astrazeneca UK Limited | 2 | $40,200 |
| Bayer | 31 | $32,202 |
| Pfizer | 18 | $28,519 |
| E.r. Squibb & Sons, L.L.C. | 3 | $19,500 |
| Astellas Pharma US Inc | 6 | $11,713 |
| Astellas Pharma Global Development | 3 | $10,000 |
| Advanced Accelerator Applications | 3 | $8,534 |
| Sanofi | 7 | $8,366 |
| Tolmar, Inc. | 3 | $7,300 |
| Johnson & Johnson | 7 | $5,619 |
| Lantheus Medical Imaging, Inc. | 5 | $4,491 |
| Janssen Scientific Affairs, LLC | 8 | $4,421 |
| Merck | 6 | $2,625 |
| Foundation Medicine, Inc. | 1 | $1,500 |
| AstraZeneca | 1 | $1,370 |
| Novartis | 5 | $467 |
| Progenics Pharmaceuticals, Inc. | 4 | $417 |
| Bayer Healthcare LLC | 1 | $150 |
| Blue Earth Diagnostics | 1 | $76 |
| AbbVie | 3 | $66 |
| Sumitomo Pharma America, Inc. | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Seagen Inc. | 1 | $28 |
| Bristol Myers Squibb | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Gilead | 1 | $12 |
How this compares
$1,736,624 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Saurabh ChhabraScottsdale$6.5M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.